Effect of Injection Site Pain in Patients Receiving Romosozumab for Osteoporosis

Effect of Injection Site Pain in Patients Receiving Romosozumab for Osteoporosis - Effect of Injection Site Pain in Patients Receiving Romosozumab for Osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052357

Enrollment

207

Registered

2023-11-01

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with osteoporosis

Interventions

Group receiving two romosozumab injections in the upper arms Group receiving two romosozumab injections in the abdomen Group receiving one romosozumab injection in the upper arm and one in the abdom

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with osteoporosis and initiated on pharmacologic therapy who are enrolled in the FUJIGOKO Study (IRB approved) and treated with romosozumab.

Exclusion criteria

Exclusion criteria: The exclusion criteria were patients with illnesses affecting bone and calcium metabolism or bone disorders other than osteoporosis, any malignant conditions, fresh fracture, scheduled surgery, severe renal dysfunction or history of cardiovascular events.

Design outcomes

Primary

Measure	Time frame
Injection site pain	—

Secondary

Measure	Time frame
Injection site reactions and treatment efficacy (BMD and BTM)	—

Countries

Japan,North America

Contacts

Public ContactKoji Ishikawa

Showa University Department of Orthopaedics Surgery

koji.ishikawa@med.showa-u.ac.jp0337848543

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026